专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210361867A1 INTEGRATED CLOSED-LOOP MEDICATION DELIVERY WITH ERROR MODEL AND SAFETY CHECK 有权
公开(公告)号：US20210361867A1
公开(公告)日：2021-11-25
申请号：US17398221
申请日：2021-08-10
申请人： Abbott Diabetes Care Inc. , Cambridge Enterprise Limited
发明人： Malgorzata E. Wilinska , Erwin S. Budiman , Gary A. Hayter , Marc B. Taub , Roman Hovorka
IPC分类号： A61M5/172 , A61B5/1495 , A61B5/145 , A61M5/142 , G16H20/17
摘要： A closed-loop system for insulin infusion overnight uses a model predictive control algorithm (“MPC”). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System (“FSN”). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.

2. 发明申请

US20190151540A1 INTEGRATED CLOSED-LOOP MEDICATION DELIVERY WITH ERROR MODEL AND SAFETY CHECK 审中-公开
公开(公告)号：US20190151540A1
公开(公告)日：2019-05-23
申请号：US16251572
申请日：2019-01-18
申请人： Abbott Diabetes Care Inc. , Cambridge Enterprise Limited
发明人： Malgorzata E. Wilinska , Erwin S. Budiman , Gary A. Hayter , Marc B. Taub , Roman Hovorka
IPC分类号： A61M5/172 , A61B5/1495 , A61M5/142 , A61B5/145
摘要： A closed-loop system for insulin infusion overnight uses a model predictive control algorithm (“MPC”). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System (“FSN”). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.

3. 发明申请

US20170080152A1 INTEGRATED CLOSED-LOOP MEDICATION DELIVERY WITH ERROR MODEL AND SAFETY CHECK 审中-公开
公开(公告)号：US20170080152A1
公开(公告)日：2017-03-23
申请号：US15193804
申请日：2016-06-27
申请人： ABBOTT DIABETES CARE INC. , CAMBRIDGE ENTERPRISE LIMITED
发明人： Malgorzata E. Wilinska , Erwin S. Budiman , Gary A. Hayter , Marc B. Taub , Roman Hovorka
IPC分类号： A61M5/172 , G06F19/00 , A61M5/142
CPC分类号： A61M5/1723 , A61B5/14532 , A61B5/1495 , A61M5/142 , A61M2005/14208 , A61M2005/14292 , A61M2005/14296 , A61M2205/50 , A61M2205/52 , A61M2205/70 , A61M2230/201 , G06F19/3468
摘要： A closed-loop system for insulin infusion overnight uses a model predictive control algorithm (“MPC”). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System (“FSN”). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.

4. 发明申请

US20140081236A1 INTEGRATED CLOSED-LOOP MEDICATION DELIVERY WITH ERROR MODEL AND SAFETY CHECK 有权
标题翻译：综合封闭环路交付与错误模型和安全检查
公开(公告)号：US20140081236A1
公开(公告)日：2014-03-20
申请号：US14083336
申请日：2013-11-18
申请人： Cambridge Enterprise Limited , Abbott Diabetes Care Inc.
发明人： Malgorzata E. Wilinska , Erwin S. Budiman , Gary A. Hayter , Marc B. Taub , Roman Hovorka
IPC分类号： A61M5/172
CPC分类号： A61M5/1723 , A61B5/14532 , A61B5/1495 , A61M5/142 , A61M2005/14208 , A61M2005/14292 , A61M2005/14296 , A61M2205/50 , A61M2205/52 , A61M2205/70 , A61M2230/201 , G06F19/00 , G06F19/3468
摘要： A closed-loop system for insulin infusion overnight uses a model predictive control algorithm (“MPC”). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System (“FSN”). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.
摘要翻译：用于胰岛素输注的闭环系统使用模型预测控制算法（“MPC”）。与MPC一起使用的是葡萄糖测量误差模型，该误差模型来自实际的葡萄糖传感器误差数据。该传感器误差数据包括传感器伪像分量，包括丢失，以及包括校准误差在内的持续误差分量，所有这些均由实验受试者实验获得。 MPC算法建议胰岛素输注每十五分钟。通过将模型计算的无噪声间质葡萄糖与与FreeStyleNavigator®连续葡萄糖监测系统（“FSN”）相关的实验衍生的瞬时和持续传感器伪像组合，可以获得传感器葡萄糖输入到MPC。在使用葡萄糖测量误差模型的MPC算法模拟过夜闭环控制期间，严重和显着低血糖的发生率分别降低了2300和200倍，表明连续葡萄糖监测技术有助于安全闭环胰岛素输送。

5. 发明申请

US20170135643A1 METHODS FOR REDUCING FALSE HYPOGLYCEMIA ALARM OCCURRENCE 审中-公开
公开(公告)号：US20170135643A1
公开(公告)日：2017-05-18
申请号：US15414550
申请日：2017-01-24
申请人： ABBOTT DIABETES CARE INC. , CAMBRIDGE ENTERPRISE LIMITED
发明人： Erwin S. Budiman , Gary A. Hayter , Marc B. Taub , Roman Hovorka , Malgorzata E. Wilinska , David Dunger
IPC分类号： A61B5/00 , G06F19/00 , A61B5/145
CPC分类号： A61B5/7221 , A61B5/14532 , A61B5/4839 , A61B5/7264 , A61B5/7275 , A61B5/746 , A61M5/1723 , A61M2005/14296 , A61M2205/18 , A61M2205/3569 , A61M2205/52 , A61M2230/201 , G06F19/3418 , G06F19/3468 , G16H15/00 , G16H50/20 , G16H50/30 , G16H50/50
摘要： A system and method for reducing the number of hypoglycemic alarms presented to a user is presented. The system and methods include use of model based state estimation and variable-delayed threshold values to balance the risk of not presenting an alarm caused by an actual hypoglycemic state with the presentation of alarms caused by artifacts in the signals produced by a continuous glucose monitor.

6. 发明授权

US11246986B2 Integrated closed-loop medication delivery with error model and safety check 有权
公开(公告)号：US11246986B2
公开(公告)日：2022-02-15
申请号：US16251572
申请日：2019-01-18
申请人： Abbott Diabetes Care Inc. , Cambridge Enterprise Limited
发明人： Malgorzata E. Wilinska , Erwin S. Budiman , Gary A. Hayter , Marc B. Taub , Roman Hovorka
IPC分类号： A61M5/172 , A61B5/1495 , A61M5/142 , A61B5/145 , G16H20/17
摘要： A closed-loop system for insulin infusion overnight uses a model predictive control algorithm (“MPC”). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System (“FSN”). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.

7. 发明授权

US09402953B2 Integrated closed-loop medication delivery with error model and safety check 有权
标题翻译：综合闭环药物输送与错误模型和安全检查
公开(公告)号：US09402953B2
公开(公告)日：2016-08-02
申请号：US14083336
申请日：2013-11-18
申请人： Abbott Diabetes Care Inc. , Cambridge Enterprise Limited
发明人： Malgorzata E. Wilinska , Erwin S. Budiman , Gary A. Hayter , Marc B. Taub , Roman Hovorka
IPC分类号： A61M5/172 , A61B5/145 , A61B5/1495 , A61M5/142
CPC分类号： A61M5/1723 , A61B5/14532 , A61B5/1495 , A61M5/142 , A61M2005/14208 , A61M2005/14292 , A61M2005/14296 , A61M2205/50 , A61M2205/52 , A61M2205/70 , A61M2230/201 , G06F19/00 , G06F19/3468
摘要： A closed-loop system for insulin infusion overnight uses a model predictive control algorithm (“MPC”). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System (“FSN”). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.
摘要翻译：用于胰岛素输注的闭环系统使用模型预测控制算法（“MPC”）。与MPC一起使用的是葡萄糖测量误差模型，该误差模型来自实际的葡萄糖传感器误差数据。该传感器误差数据包括传感器伪像分量，包括丢失，以及包括校准误差在内的持续误差分量，所有这些均由实验受试者实验获得。 MPC算法建议胰岛素输注每十五分钟。通过将模型计算的无噪声间质葡萄糖与与FreeStyleNavigator®连续葡萄糖监测系统（“FSN”）相关的实验衍生的瞬时和持续传感器伪像组合，可以获得传感器葡萄糖输入到MPC。在使用葡萄糖测量误差模型的MPC算法模拟过夜闭环控制期间，严重和显着低血糖的发生率分别降低了2300和200倍，表明连续葡萄糖监测技术有助于安全闭环胰岛素输送。

8. 发明申请

US20220280718A1 MEDICAL DEVICE ANTENNA SYSTEMS HAVING EXTERNAL ANTENNA CONFIGURATIONS 有权
公开(公告)号：US20220280718A1
公开(公告)日：2022-09-08
申请号：US17750500
申请日：2022-05-23
申请人： ABBOTT DIABETES CARE INC.
发明人： Nathan C. Crouther , Marc B. Taub , Lei He
IPC分类号： A61M5/172 , A61M5/142 , H01Q1/22 , H01Q1/27 , A61B5/00 , A61B5/145 , H01Q5/48
摘要： A medical device includes an antenna external to a case, package, or encapsulant for the electronic systems of the medical device. In one embodiment, a diabetes infusion pump is enclosed within a metal case, the pump including a processor and a communication module for wireless communications. An antenna is disposed in the delivery tubing of the pump outside the case with an antenna feed interconnecting the external antenna with the internal communication module. In another aspect, a thin film antenna is formed on the outer surface of the case in which a physiological parameter sensor, such as a glucose sensor, is enclosed. Multiple antennas may be used for communications on different frequencies.

9. 发明申请

US20220118180A1 Usability Features for Integrated Insulin Delivery System 有权
公开(公告)号：US20220118180A1
公开(公告)日：2022-04-21
申请号：US17567684
申请日：2022-01-03
申请人： ABBOTT DIABETES CARE INC.
发明人： Mark Sloan , Marc B. Taub , Gary A. Hayter , Wesley Scott Harper , Erwin S. Budiman , Charles Wei
IPC分类号： A61M5/172 , A61B5/145 , A61B5/00 , A61M5/142 , G16H50/50 , G16H20/17 , G08B21/04 , G08B21/18
摘要： Methods and systems for delaying alarms that include detecting an analyte level using an analyte sensor; and delaying the annunciation of an analyte alarm after the analyte level crosses an analyte threshold, wherein the delay is based on one or both of (1) a magnitude of difference between the analyte level and the analyte threshold and (2) a duration of time in which the analyte level has crossed the analyte threshold.

10. 发明授权

US11166654B2 Method of optimizing efficacy of therapeutic agent 有权
公开(公告)号：US11166654B2
公开(公告)日：2021-11-09
申请号：US16116977
申请日：2018-08-30
申请人： Abbott Diabetes Care Inc.
发明人： Thomas A. Peyser , Marc B. Taub , R. Curtis Jennewine , Timothy Christian Dunn , Kerstin Rebrin
IPC分类号： A61B5/1486 , A61B5/145 , A61B5/00
摘要： Method and device for outputting one or more signals associated with a monitored analyte level of an individual, the one or more signals including a substantially real time monitored analyte level and a rate of change information associated with the monitored analyte level, outputting a carbohydrate intake event indication, determining one or more data associated with one or more therapy information related to the monitored analyte level and the meal event indication, and outputting the determined one or more data over the outputted one or more signals associated with the monitored analyte level and the carbohydrate intake event indication are provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式